---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-012876"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T20:14:58.285192+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals appoints Robert Chen as CFO effective May 16, 2022, replacing Marc Bregman

## Summary
- Robert Chen named CFO; base salary $250,000/year; at-will employment starting May 16, 2022.
- Chen receives stock options for 900,000 shares, vesting over 3 years from issuance.
- Prior CFO Marc Bregman ceased services as Secretary and Treasurer effective April 29, 2022.
- Chen brings 20+ years life science finance experience, most recently VP Finance at KBP Biosciences.

## SEC filing metadata
- accession: 0001493152-22-012876
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315222012876/0001493152-22-012876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315222012876/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-012876
- JSON: https://secwatch.observer/filing/0001493152-22-012876.json
- Plain text: https://secwatch.observer/filing/0001493152-22-012876.txt

## Key facts
- Executive change
  Robert Chen was appointed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 5, 2022, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Robert Chen to serve as the Registrants’ Chief Financial Officer, replacing Marc Bregman, who served as the Registrant’s Chief Financial Officer effective May 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315222012876/0001493152-22-012876-index.htm
- Executive change
  Marc Bregman departed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
  - Action: replaced
  - Role: Chief Financial Officer
  source text: Effective as of May 16, 2022, Mr. Chen replaced Mr. Bregman as the Registrant’s Chief Financial Officer, and Mr. Bregman, who also served as the Registrant’s Secretary and Treasurer, ceased providing services to the Registrant in such capacities as of April 29, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315222012876/0001493152-22-012876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.